Q/C Technologies, Inc. (QCLS) is a clinical-stage/pre-revenue company that pivoted in September 2025 from pharmaceutical development (Isomyosamine, Supera-CBD) to quantum-class laser-based computing infrastructure for cryptocurrency and AI applications, anchored by an exclusive license from LightSolver Ltd. acquired via the MIPA transaction. As of March 31, 2026, the company reported cash of $1.13 million and marketable securities of $11.85 million, working capital of $10.02 million, and stated stockholders' equity of $20.7 million against an accumulated deficit of $145.65 million. Under liquidation lens, recovery to equity is structurally impaired by the composition of the asset base: the primary balance-sheet asset is the LightSolver exclusive license, capitalized at $14.09 million (total purchase price allocated entirely to an indefinite-lived intangible), which receives a 0% recovery haircut under liquidation conventions. Marketable securities ($11.85 million) are the dominant liquid asset and receive near-full recovery, but face-value liabilities significantly offset this. The company carries a bifurcated embedded derivative liability on the Series H Preferred Stock, estimated at $1.65 million fair value at March 31, 2026 (up $510K during Q1 2026), plus a contingent consideration derivative liability from the MIPA acquisition initially valued at $9.38 million as of the September 2025 acquisition date, which is remeasured each period. The filing does not separately disclose the Q1 2026 fair value of the contingent consideration liability in the XBRL tags available; it is discussed in MD&A and footnotes but the current-period remeasurement amount is not explicitly broken out in the body text beyond the change-in-FV segment table showing a $510K derivative loss attributable to the computing segment. The Series H Preferred Stock (7,000 shares outstanding, $7 million gross proceeds, 7% dividend, 106% redemption premium, with full ratchet anti-dilution warrants and triggering event cash redemption rights at premium) represents a senior preferred obligation that stays at face value under liquidation and ranks senior to common equity and junior to Series F/F-1/G. Outstanding common stock warrants total approximately 10.35 million shares at a weighted average exercise price of $6.37, classified as equity, not liabilities, so they do not directly inflate the liability stack but represent significant dilution overhang. The MFFAIS CLV/LLV/OLV are all reported at negative $4.55 million, consistent with the intangible-heavy asset mix producing negative equity recovery once the zero-haircut intangible is excluded from the asset side and all preferred obligations and derivative liabilities are held at face. Zero revenue has been generated in any period. Operating cash burn for Q1 2026 was $3.29 million. The filing does not separately tag balance-sheet line items in XBRL for this period; all material balance-sheet data is presented in narrative and MD&A only.
▼ Community Notes